Research programme: brain cancer therapies - D-Pharm
Alternative Names: DP-242; DP-243Latest Information Update: 08 Nov 2006
At a glance
- Originator D-Pharm
- Class
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Brain cancer
Most Recent Events
- 27 Sep 2006 Discontinued - Preclinical for Brain cancer in Israel (unspecified route)
- 29 Oct 2001 Preclinical development for Brain cancer in Israel (Unknown route)